Health Care & Life Sciences » Biotechnology | Kitov Pharmaceuticals Holdings Ltd.

Kitov Pharmaceuticals Holdings Ltd.

Kitov Pharmaceuticals Holdings Ltd. ADR
Stock Exchange NASDAQ Stock Market
EPS
$7.81
Market Cap
$18.85 M
Shares Outstanding
971.89 K
Public Float
-

Profile

Address
One Azrieli Center
Tel Aviv TA 670110
Israel
Employees -
Website http://www.kitovpharma.com
Updated 07/08/2019
Kitov Pharma Ltd. is a development stage biopharmaceutical company, which engages in drug development. The firm offers Consensi and NT219. Consensi is intended to treat osteoarthritis pain and hyper tension simultaneously, while NT219 is a cancer therapy drug that delivers anti-tumor effects and increasing survical in various cancer models.

Financials

View All
Created with Highcharts 5.0.14Kitov Pharmaceuticals Holdings Ltd. ADRNet Income. Fiscal year is January-December. All values ILS Thousands.9 4859 48519 66719 66716 32516 32546 54546 54544 14244 14218 69518 695201320142015201620172018010k20k30k40k50k

John Paul Waymack
Chairman & Chief Medical Officer
Isaac Israel
Chief Executive Officer & Director